secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001104659-25-079459
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel receives positive FDA pre-sNDA comments for BXCL501 at-home use; sNDA on track for Q1 2026
--------------------------------------------------------------------------------

- FDA provided positive written feedback on August 14, 2025 for BXCL501 sNDA in agitation associated with bipolar disorders or schizophrenia for outpatient setting.
- Pre-sNDA meeting originally scheduled for August 20, 2025 is cancelled as objectives accomplished based on FDA written responses.
- Company believes sNDA regulatory package will be sufficient; submission remains on track for first quarter of 2026.
- This expands potential use of BXCL501 (IGALMI) from inpatient to at-home treatment for acute agitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925079459/0001104659-25-079459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925079459/tm2523368d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-079459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer